Newark, New Castle, USA, April 28, 2023 (GLOBE NEWSWIRE) -- In accordance with the most recent analysis by Growth Plus Reports, the global market for multifocal motor neuropathy is expected to expand ...

DelveInsight’s, “Multifocal Motor Neuropathy Pipeline Insight, 2025” report provides comprehensive insights about 3+ companies and 3+ pipeline drugs in Multifocal Motor Neuropathy pipeline landscape.

This page lists all known medications that could potentially lead to 'Multifocal motor neuropathy' as a side effect. It's important to note that mild side effects are quite common with medications.

Multifocal motor neuropathy is an acquired immune-mediated demyelinating neuropathy that is characterised by slowly progressive weakness, cramping and fasciculations and lack of significant sensory ...

ARDA study data show potential for empasiprubart to drive functional improvement and reduced risk of relapse for multifocal motor neuropathy (MMN) patients ADHERE+ data show durability of functional ...

A scientific team supported by the National Institutes of Health has created a tiny, bioengineered 3-D model that mimics the biology of chronic inflammatory demyelinating polyneuropathy and multifocal ...

June 27, 2012 — Immune Globulin Infusion (Human), 10% (Gammagard Liquid, Baxter International, Inc), has been approved by the US Food and Drug Administration (FDA) as a treatment for multifocal motor ...

Amsterdam, the Netherlands—June 20, 2023—argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today ...

Baxter International Inc. (NYSE:BAX) today announced that the U.S. Food and Drug Administration (FDA) has approved GAMMAGARD LIQUID 10% [Immune Globulin Infusion (Human)] as a treatment for multifocal ...

Multifocal Motor Neuropathy (MMN) is a rare condition in which multiple motor nerves are attacked by one’s immune system. This attack causes weakness of muscles but not loss of sensation. The ...